Please login to the form below

Not currently logged in
Email:
Password:

fasiglifam

This page shows the latest fasiglifam news and features for those working in and with pharma, biotech and healthcare.

Takeda drops prostate cancer drug in phase III

Takeda drops prostate cancer drug in phase III

The Japanese company also dropped diabetes candidate fasiglifam earlier this year, but it has a good crop of other products at, or nearing, commercialisation.

Latest news

  • Omontys terminal as Takeda switches off support Omontys terminal as Takeda switches off support

    Meanwhile, Takeda has had a bad run of luck with its late-stage pipeline of late, dropping diabetes candidate fasiglifam earlier this year.

  • Takeda pipeline hit by fasiglifam failure Takeda pipeline hit by fasiglifam failure

    Diabetes candidate had been set for a 2015 launch. Takeda has suffered a major pipeline setback after deciding to terminate development of fasiglifam, a candidate therapy for diabetes that had been ... The pharma company took the decision after phase III

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics